SpringWorks Therapeutics Announces Data to be Presented at t

– Results from pivotal Phase 2b ReNeu trialofmirdametinib in patients with NF1-PN to be presented in an oral presentation –

Related Keywords

United States , Philadelphia , Pennsylvania , American , Christopherl Moertel , Betty Jayne Dahlberg , Jim Cassidy , Samantha Hilson Sandler , University Of Washington , Twitter , Children Tumor Foundation , Neurofibromatosis Program , Linkedin , Fred Hutchinson Cancer Center , Health Supervision For Children With Neurofibromatosis Type , European Commission , Clinical Research Division , Springworks Therapeutics Inc , European Medicines Agency , Us Department Of Commerce , American Society Of Clinical Oncology , University Of Minnesota School Medicine , Drug Administration , Desmoid Tumor Working Group , Nasdaq , Prada , Youtube , Works Therapeutics , Clinical Oncology , Annual Meeting , Chief Medical Officer , Oral Presentations , Numeric Rating , Medical Director , Pediatric Neuro Oncology , Betty Jayne Dahlberg Professor , Minnesota School , Elizabeth Loggers , Associate Professor , Palliative Care , Associate Clinical Professor , Orphan Drug , Fast Track , Rare Pediatric Disease , New Drug Application , Marketing Authorization Application , Response Evaluation Criteria , Solid Tumors , Melanoma Skin Cancers , Private Securities Litigation Reform Act , Springwork Quarterly Report , Orphanetj Rare , Adults With , Related Plexiform , Children With Neurofibromatosis Type , Dei Tos , Soft Tissue Tumours , Tumor Working , Report Series , Rare Diseases ,